News
Istari Oncology to Participate in Upcoming Virtual Investor Conferences
DURHAM, NC – September 7, 2021 – Istari Oncology, Inc., a clinical-stage biotechnology company focused…
Istari Oncology Initiates Its Phase I/II Sub-Study Evaluating PVSRIPO in Patients with Head and Neck Cancer
DURHAM, NC – August 17, 2021 – Istari Oncology, Inc., a clinical-stage biotechnology company focused…
Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma
Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced…
Istari Oncology Hires Jamie Iudica as Chief Manufacturing Officer Expanding the Company’s Growing Executive Team
Istari Oncology Hires Jamie Iudica as Chief Manufacturing Officer Expanding the Company’s Growing Executive Team…
Istari Oncology to Present Data from its PVSRIPO Immunotherapy Platform at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
Istari Oncology to Present Data from its PVSRIPO Immunotherapy Platform at the American Society of…
Istari Oncology Honored as “Best Early Stage Product Development Company” in the Triangle Business Journal’s Life Sciences Awards
Istari Oncology Honored as "Best Early Stage Product Development Company" in the Triangle Business Journal's…
Istari Oncology Announces Publication of Phase 1 Data Showing PVSRIPO Immunotherapy Leads to Objective Responses in Patients with Treatment-Refractory Melanoma
Istari Oncology Announces Publication of Phase 1 Data Showing PVSRIPO Immunotherapy Leads to Objective Responses…
Istari Oncology Announces FDA Clearance of IND to Initiate LUMINOS-103
Istari Oncology Announces FDA Clearance of IND to Initiate LUMINOS-103: A Basket Trial Evaluating the…
Istari Oncology Abstracts to be Presented at the American Association for Cancer Research 2021 Annual Meeting
Istari Oncology Abstracts to be Presented at the American Association for Cancer Research (AACR) 2021…
Istari Oncology Announces First Patient Dosed in the LUMINOS-102 Phase 2 Clinical Trial of PVSRIPO
Istari Oncology Announces First Patient Dosed in the LUMINOS-102 Phase 2 Clinical Trial of PVSRIPO…